RT Journal Article SR Electronic T1 A feasible and more efficient SARS-Cov-2 vaccine allocation to states and counties in the USA JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.17.21253793 DO 10.1101/2021.03.17.21253793 A1 Anthony R. Ives A1 Claudio Bozzuto YR 2021 UL http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253793.abstract AB While discussion of vaccine allocation has centered around who should be prioritized (e.g., health care personnel and the elderly), we argue that vaccines should also be allocated to jurisdictions (e.g., counties within the USA) with the greatest immunization thresholds needed for ending the epidemic. At the current rate of vaccine distribution (March 15, 2021), universal herd immunity in the USA could be reached in roughly 4.5 months. However, distributing vaccines according to where the virus spreads more easily (dense counties with high R0 values), herd immunity would be reached simultaneously in all counties almost two months earlier and would require roughly 40% fewer vaccine doses. Furthermore, under the current distribution strategy densely populated counties would reach herd immunity last, with negative epidemiological and socio-economic consequences. In sum, it would be more fair and efficient to distribute vaccines to jurisdictions that need them most to reach herd immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NASA-AIST-80NSSC20K0282 (A.R.I)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are published and referenced in the main text. https://doi.org/10.6084/m9.figshare.13322882.v1 http://measureofamerica.org